High‐Mobility Group Box‐1 and Liver Disease
Year: 2018
Type: review
Abstract: High-mobility group box-1 (HMGB1) is a ubiquitous protein. While initially thought to be simply an architectural protein due to its DNA-binding ability, evidence from the last decade suggests that HMGB1 is a key protein participating in the pathogenesis of acute liver injury and chronic liver disease. When it is passively released or actively secreted after injury, HMGB1 acts as a damage-associated molecular pattern that communicates injury and inflammation to neighboring cells by the receptor for advanced glycation end products or toll-like receptor 4, among others. In the setting of acute liver injury, HMGB1 participates in ischemia/reperfusion, sepsis, and drug-induced liver injury. In the context of chronic liver disease, it has been implicated in alcoholic liver disease, liver fibrosis, nonalcoholic steatohepatitis, and hepatocellular carcinoma. Recently, specific posttranslational modifications have been identified that could condition the effects of the protein in the liver. Here, we provide a detailed review of how HMGB1 signaling participates in acute liver injury and chronic liver disease.
Source: Hepatology Communications
DOI: 10.1002/hep4.1223
Authors: Harriet Gaskell, Xiaodong Ge, Natalia Nieto
Institution: University of Illinois Chicago
Language: English
Subfield: Clinical Biochemistry
Domain: Life Sciences
Keywords: HMGB1, high mobility group box 1, acute liver injury, chronic liver disease, damage-associated molecular patterns, RAGE, TLR4, ischemia-reperfusion injury, sepsis, drug-induced liver injury, alcoholic liver disease, liver fibrosis, nonalcoholic steatohepatitis, hepatocellular carcinoma, post-translational modification, inflammation
Open Access status: gold
Estimated APC paid: $2,700
OpenAlex ID: W2890644813
